A Phase II Study of the Combination of Bevacizumab, Pertuzumab, and Octreotide LAR for Patients with Advanced Neuroendocrine Cancers-Reference-Cited by-同舟云学术

A Phase II Study of the Combination of Bevacizumab, Pertuzumab, and Octreotide LAR for Patients with Advanced Neuroendocrine Cancers

Published:2016-04-29 Issue:5 Volume:34 Page:213-219
ISSN:0735-7907
Container-title:Cancer Investigation
language:en
Short-container-title:Cancer Investigation

Author:

Bendell Johanna C.¹²,Zakari Ahmed³,Lang Evan¹⁴,Waterhouse David¹⁴,Flora Douglas¹⁴,Alguire Kathryn⁵,McCleod Michael¹⁶,Peacock Nancy¹²,Ruehlman Peter¹⁴,Lane Cassie M.¹,Earwood Chris¹,Shih Kent¹²

Affiliation:

1. Sarah Cannon Research Institute, Nashville, TN, USA

2. Tennessee Oncology, PLLC, Nashville, TN, USA

3. Florida Hospital Cancer Institute, Orlando, FL, USA

4. OHC (Oncology Hematology Care), Cincinnati, OH, USA

5. Grand Rapids Oncology Program, Grand Rapids, MI, USA

6. Florida Cancer Specialists, Ft. Myers, FL, USA

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.3109/07357907.2016.1174257

Reference15 articles.

1. Fluorouracil, Doxorubicin, and Streptozocin in the Treatment of Patients With Locally Advanced and Metastatic Pancreatic Endocrine Carcinomas

2. Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors

3. Everolimus for Advanced Pancreatic Neuroendocrine Tumors

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Angiogenesis and Pancreatic Cancer: Novel Approaches to Overcome Treatment Resistance;Current Cancer Drug Targets;2024-11

2. ETV6-NTRK2 Fusion in a Patient With Metastatic Pulmonary Atypical Carcinoid Successfully Treated With Entrectinib: A Case Report and Review of the Literature;Clinical Lung Cancer;2024-05

3. From biology to clinical practice: antiproliferative effects of somatostatin analogs in neuroendocrine neoplasms;Therapeutic Advances in Medical Oncology;2024-01

4. Combination Systemic Therapies in Advanced Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): A Comprehensive Review of Clinical Trials and Prospective Studies;Biology;2023-07-30

5. Octreotide long-acting release (LAR) in combination with other therapies for treatment of neuroendocrine neoplasia: a systematic review;Journal of Gastrointestinal Oncology;2021-04